Your browser doesn't support javascript.
loading
Stratification and therapeutic potential of PML in metastatic breast cancer.
Martín-Martín, Natalia; Piva, Marco; Urosevic, Jelena; Aldaz, Paula; Sutherland, James D; Fernández-Ruiz, Sonia; Arreal, Leire; Torrano, Verónica; Cortazar, Ana R; Planet, Evarist; Guiu, Marc; Radosevic-Robin, Nina; Garcia, Stephane; Macías, Iratxe; Salvador, Fernando; Domenici, Giacomo; Rueda, Oscar M; Zabala-Letona, Amaia; Arruabarrena-Aristorena, Amaia; Zúñiga-García, Patricia; Caro-Maldonado, Alfredo; Valcárcel-Jiménez, Lorea; Sánchez-Mosquera, Pilar; Varela-Rey, Marta; Martínez-Chantar, Maria Luz; Anguita, Juan; Ibrahim, Yasir H; Scaltriti, Maurizio; Lawrie, Charles H; Aransay, Ana M; Iovanna, Juan L; Baselga, Jose; Caldas, Carlos; Barrio, Rosa; Serra, Violeta; Vivanco, Maria dM; Matheu, Ander; Gomis, Roger R; Carracedo, Arkaitz.
Afiliación
  • Martín-Martín N; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Piva M; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Urosevic J; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain.
  • Aldaz P; Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain.
  • Sutherland JD; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Fernández-Ruiz S; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Arreal L; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Torrano V; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Cortazar AR; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Planet E; Biostatistics and Bioinformatics Unit, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain.
  • Guiu M; School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
  • Radosevic-Robin N; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain.
  • Garcia S; ERTICa Research Group, University of Auvergne EA4677, Clermont-Ferrand, France.
  • Macías I; Biodiagnostics Laboratory OncoGenAuvergne, Pathology Unit, Jean Perrin Comprehensive Cancer Center, 63000 Clermont-Ferrand, France.
  • Salvador F; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France.
  • Domenici G; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Rueda OM; Oncology Programme, Institute for Research in Biomedicine (IRB-Barcelona), 08028 Barcelona, Spain.
  • Zabala-Letona A; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Arruabarrena-Aristorena A; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
  • Zúñiga-García P; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Caro-Maldonado A; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Valcárcel-Jiménez L; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Sánchez-Mosquera P; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Varela-Rey M; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Martínez-Chantar ML; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Anguita J; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Ibrahim YH; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).
  • Scaltriti M; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Lawrie CH; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).
  • Aransay AM; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Iovanna JL; IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain.
  • Baselga J; Experimental Therapeutics Group, Vall d'Hebron University Hospital, 08035 Barcelona, Spain.
  • Caldas C; Weill Cornell Medicine, New York 10021, USA.
  • Barrio R; Human Oncology and Pathogenesis Program, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 10065 New York, USA.
  • Serra V; Oncology Area, Biodonostia Institute, 20014 San Sebastian, Spain.
  • Vivanco Md; IKERBASQUE, Basque foundation for science, 48013 Bilbao, Spain.
  • Matheu A; CIC bioGUNE, Bizkaia Technology Park, Bulding 801a, 48160 Derio, Spain.
  • Gomis RR; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd).
  • Carracedo A; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, CNRS UMR 7258, Aix-Marseille University and Institut Paoli-Calmettes, Parc Scientifique et Technologique de Luminy, 13288 Marseille, France.
Nat Commun ; 7: 12595, 2016 08 24.
Article en En | MEDLINE | ID: mdl-27553708
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína de la Leucemia Promielocítica Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína de la Leucemia Promielocítica Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article